A new meta-analysis study looking at prior studies of PARP inhibitors in patients with metastatic castration-resistant prostate cancer and an inherited gene mutation showed: Learn more at: https://pubmed.ncbi.nlm.nih.gov/39848867/ Reference: Naqvi, et al. Eur Urol. 2025:S0302-2838(24)02760-X. PMID: 39848867.
Permanent link to this article: https://inheritedcancer.net/post52125/
Lynch syndrome related cancers have a distinct immune profile. They are generally “immunogenic”, meaning there might be opportunities to develop immune-interception strategies to prevent cancer. What is cancer “interception”? A new study based on work in mice showed that an EZH2 inhibitor (called GSK503) given over 9 weeks in mice lowered the number of adenomas …
Permanent link to this article: https://inheritedcancer.net/post50525/
